fbpx

Day

December 20, 2018
Veloxis Pharmaceuticals announced today that the U.S. Food & Drug Administration (FDA) approved a new indication for Envarsus XR (tacrolimus extended-release tablets) to prevent organ rejection in de novo kidney transplant patients in combination with other immunosuppressants. This indication is commonly referred to as the de novo indication. Envarsus XR was approved for the prophylaxis of organ rejection in...

Nyheder

Research project to investigate potential link between headache pills and early-stage spontaneous abortion
6. January 2020
Cancer patients donate living brain cells to scientists
17. December 2019
The Lundbeck Foundation grants 60 million Danish kroner to bold scientific ideas
11. December 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge